This stock no longer trades (delisted May 22, 2026)

Delisted / no longer publicly traded (per market data provider) Everything below is based on the last available data — treat it as historical, not a live read.

Biogen

IDP.DE

Drug Manufacturers - General · Healthcare

Exchange

Frankfurt Stock Exchange

Winston Score

Historical score — this stock no longer trades, so the score is frozen at the last available data.

Data as of Aug 23, 2026 · filings through Mar 31, 2026

How the score breaks down

Quality

Good

Growth

Mixed

Cash Flow

Exceptional

Stability

Strong

Valuation

Weak

Winston Score History

The full picture

Biogen is a biotechnology company that discovers and sells medicines for serious brain and nervous system diseases. Its main products treat multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease — conditions that affect millions of people worldwide. The company's Alzheimer's drug Leqembi, developed with Japanese partner Eisai, is one of the first treatments shown to slow the disease's progression.

Biogen makes money by selling prescription drugs directly to hospitals, clinics, and specialty pharmacies, which then reach patients. It operates globally, with the United States generating the majority of its roughly $9–10 billion in annual revenue. The company's moat comes from its deep expertise in neuroscience and a portfolio of patents that protect its drugs from cheap generic competition for years. The biggest growth driver is the commercial rollout of Leqembi, but the main risk is that several of Biogen's older multiple sclerosis drugs face growing competition from generics and rival treatments, which has been pressuring revenue.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+1.9% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+31.5% YoY

YoY Growth Rate

Strong earnings growth

Insider Activity

0.3%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

€4.7B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Biogen is growing revenue at 2% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

73.3%

Premium pricing power — 73.3% gross margin

Profit after running costs

Operating Margin

18.6%

Healthy — 18.6% operating margin

Return on the money invested

ROCE

9.3%

Below par — 9.3% return on capital

ROIC between 5% and 15%. They earn 5 to 15 cents back per year on every dollar invested.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+0.6%

Nearly flat sales (+0.6% YoY)

Profit growth

EPS YoY

-7.9%

Earnings shrinking (-7.9% YoY)

Slight earnings drop. Typical near a cyclical low.

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

189%

Turns 189% of profit into real cash

Spare cash per sale

FCF Margin

24.5%

Converts sales into free cash efficiently (24.5%)

Free cash flow margin above 20%. Out of every $100 in sales, more than $20 is real cash they keep.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.34

Conservative — low debt load (0.34)

Covers its interest

Interest Cover

8.40x

Comfortably covers interest (8.4x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

34.1x

no trend

Pricey — P/E 34.1

P/E above the market average. People are paying up for expected growth.

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial